HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy

JAMA

Volumn 286, Issue 2, 2001, Pages 196-207

  Hermankova, Monika ^a   Ray, Stuart C ^a   Ruff, Christian ^a   Powell Davis, Monique ^a   Ingersoll, Roxann ^a   D'Aquila, Richard T ^b   Quinn, Thomas C ^a,c   Siliciano, Janet D ^a   Siliciano, Robert F ^a   Persaud, Deborah ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; GENETIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEASUREMENT; MOLECULAR CLONING; PHYLOGENY; PLASMA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TREATMENT FAILURE; VIREMIA; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 0034946886     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.2.196     Document Type: Article

References (47)

1. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
3. Decay characteristics of HIV-1-infected compartments during combination therapy
4. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection
5. Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants
6. HIV-1 dynamics in children
7. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens
8. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
9. Antiretroviral drug resistance testing in adult HIV-1 infection
10. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
11. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
12. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
13. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
14. HIV infection: How effective is drug combination treatment?
15. Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
16. Time of initiation of antiretroviral therapy: Impact on HIV-1 viraemia
17. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy
18. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy
19. In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency
20. Quantitation of latent tissue reservoirs and total body viral load in HIV-1 infection
21. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
22. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
23. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
24. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children
25. Maintaining the integrity of human immunodeficiency virus sequence databases
26. Virus "quasispecies": Making a mountain out of a molehill?
27. The neighbor-joining method: A new method for reconstructing phylogenetic trees
28. Confidence limits on phylogenies: An approach using the bootstrap
29. Antiretroviral resistance during successful therapy of human immunodeficiency virus type 1 infection
30. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides
31. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase
32. A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V
33. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy
34. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
35. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
36. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine
37. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
38. Emergence of zidovudine resistance in HIV-infected patients receiving stavudine
39. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
40. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor
41. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy
42. HIV-1 rebound after antiretroviral therapy
43. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
44. Human immunodeficiency virus type 1 quasi species that rebound after discontinuation of highly active antiretroviral therapy are similar to the viral quasi species present before initiation of therapy
45. HIV-1: Gambling on the evolution of drug resistance?
46. Linkage disequilibrium test implies a large effective population number for HIV in vivo